SS-31 (Elamipretide) Mitochondrial Support for Gut: Evidence Review
What's breaking down
The body is always doing two things at once: breaking down (degeneration) and building back (regeneration). A condition persists when breakdown outruns repair. Most drugs used for symptoms suppress a signal (pain, acid, anxiety, inflammation) without fixing the tissue that caused the signal. Peptides in this ledger are studied for repair pathways: new blood vessels, repair-cell migration, nerve regrowth, gut lining, neural connections. This article maps one compound through that frame — what it is, how it is proposed to work, what evidence exists, and what people report.
Why SS-31 (Elamipretide) might help you
- Therefore for you: If that layer is part of your problem, SS-31 (Elamipretide) is discussed because it targets repair (tissue) — not because it masks pain.
How these fit together
Single-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.
- SS-31 (Elamipretide) → mitochondrial
What the evidence actually shows
This is a count of what is in this ledger — not a claim about all research worldwide.
- Scientific sources catalogued (PubMed, trials, reviews): 4
- Claims tagged human evidence: 1
- Claims tagged preclinical (animal/lab): 2
- Claims tagged anecdotal: 0
- Reddit posts catalogued: 0
- X posts catalogued: 0
- Other anecdote sources (YouTube, Instagram, etc.): 0
- Total sources in chain: 4
Logic: No social posts catalogued yet — we cannot report what people are saying on Reddit or X from this ledger.
Quantified confidence (this ledger): 0.3 / 1.00 — low — animal and anecdote heavy
Formula: human claims×0.12 + preclinical×0.04 + anecdote×0.015 + studies (capped). This is not clinical certainty — it measures how much graded evidence is catalogued here.
What scientists say
Elamipretide: A Review of Its Structure, Mechanism, and Therapeutic Potential (source s1)
Details cardiolipin binding and mitochondrial stabilization mechanism.
Evidence type: Published research.
Mycophenolic Acid Induces the Intestinal Epithelial Barrier Dysfunction (source s2)
Direct preclinical evidence on intestinal epithelial cells.
Evidence type: Animal or lab work — shows mechanism or early signal, not proof in people.
SS-31 Peptide | Benefits, Safety & Buying Advice [2026] (source s3)
Confirms lack of human gut data across clinical development.
Evidence type: Tagged human evidence in this ledger — check sample size and design.
Elamipretide (SS-31) improves mitochondrial dysfunction, synaptic and memory impairment induced by lipopolysaccharide in mice (source s4)
LPS model with mitochondrial endpoints.
Evidence type: Animal or lab work — shows mechanism or early signal, not proof in people.
---
Not medical advice. Counts and quotes are from this article's hash-chained ledger. Anecdote = real reports, not proof. Animal studies ≠ human proof.
Evidence ledger 4 · tier-ranked · API
Model review1 contributions · 1 modelExpand the recursive review layer
/api/articles/ss-31-gut/contributionsAsk this article · 6 suggested prompts
Text the build (+14245134626) or WhatsApp — slug|question creates a question node. Paste evidence with ingest slug|q:NODE_ID|your paste.